Depomed Inc. (NASDAQ:DEPO) had its price objective hoisted by stock analysts at Mizuho from $23.00 to $27.00 in a research report issued on Friday. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. Mizuho’s price target points to a potential upside of 10.93% from the company’s current price.

Several other equities analysts have also commented on DEPO. Janney Montgomery Scott raised their price objective on Depomed from $20.13 to $28.00 and gave the company a “hold” rating in a research report on Thursday, May 26th. Cantor Fitzgerald restated a “buy” rating on shares of Depomed in a report on Wednesday, June 22nd. Royal Bank Of Canada restated a “hold” rating on shares of Depomed in a report on Monday, July 11th. Leerink Swann restated a “positive” rating on shares of Depomed in a report on Monday, July 18th. Finally, Piper Jaffray Cos. downgraded Depomed from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $21.00 to $18.00 in a report on Wednesday, July 27th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $22.65.

Shares of Depomed (NASDAQ:DEPO) opened at 24.34 on Friday. The firm’s 50-day moving average is $20.61 and its 200 day moving average is $18.30. Depomed has a 12-month low of $12.25 and a 12-month high of $29.44. The stock’s market capitalization is $1.49 billion.

Depomed (NASDAQ:DEPO) last announced its quarterly earnings data on Wednesday, August 3rd. The specialty pharmaceutical company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.26 by $0.01. The business earned $116.70 million during the quarter, compared to analyst estimates of $118.20 million. Depomed had a positive return on equity of 3.71% and a negative net margin of 16.89%. The company’s revenue for the quarter was up 23.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.27 earnings per share. On average, equities research analysts forecast that Depomed will post $1.21 EPS for the current fiscal year.

In other Depomed news, CFO August J. Moretti sold 5,000 shares of the business’s stock in a transaction dated Wednesday, August 10th. The stock was sold at an average price of $21.40, for a total transaction of $107,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Thadd M. Vargas sold 26,290 shares of the business’s stock in a transaction dated Wednesday, August 10th. The shares were sold at an average price of $20.92, for a total value of $549,986.80. Following the sale, the vice president now owns 84,336 shares of the company’s stock, valued at $1,764,309.12. The disclosure for this sale can be found here. Company insiders own 5.12% of the company’s stock.

Several large investors have recently added to or reduced their stakes in DEPO. Legal & General Group Plc increased its stake in Depomed by 29.3% in the first quarter. Legal & General Group Plc now owns 15,110 shares of the specialty pharmaceutical company’s stock worth $211,000 after buying an additional 3,423 shares in the last quarter. Consonance Capital Management LP purchased a new stake in Depomed during the first quarter worth about $38,396,000. Geode Capital Management LLC increased its stake in Depomed by 6.7% in the first quarter. Geode Capital Management LLC now owns 414,513 shares of the specialty pharmaceutical company’s stock worth $5,774,000 after buying an additional 26,160 shares in the last quarter. UBS Asset Management Americas Inc. increased its stake in Depomed by 17.7% in the first quarter. UBS Asset Management Americas Inc. now owns 31,896 shares of the specialty pharmaceutical company’s stock worth $444,000 after buying an additional 4,800 shares in the last quarter. Finally, UBS Group AG increased its stake in Depomed by 13.1% in the first quarter. UBS Group AG now owns 74,874 shares of the specialty pharmaceutical company’s stock worth $1,043,000 after buying an additional 8,662 shares in the last quarter.

Depomed Company Profile

5 Day Chart for NASDAQ:DEPO

Receive News & Ratings for Depomed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.